Cellectar Biosciences Reports Top-Line Response Rate Of 30% From R/R Multiple Myeloma Cohort In Ongoing Phase 2 Study Of CLR 131: 1 Patient Achieved Very Good PArtial Response, All Patients Showed At Least Stable Disease